Recombinant Human S100P/S100E Protein | PKSH030800

Recombinant Human S100P/S100E Protein | PKSH030800 | Gentaur US, UK & Europe Disrtribition

Synonyms: Protein S100-P; Protein S100-E; S100 Calcium-Binding Protein P; S100P; S100E; MIG9

Active Protein: N/A

Activity: A DNA sequence encoding the mature form of human S100P (P25815) (Met 1-Lys 95) was expressed and purified.

Protein Construction: A DNA sequence encoding the mature form of human S100P (P25815) (Met 1-Lys 95) was expressed and purified.

Fusion Tag:

Species: Human

Expressed Host: E.coli

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 97 % as determined by reducing SDS-PAGE.

Endotoxin: Please contact us for more information.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 10.4 kDa

Formulation: Lyophilized from sterile PBS, pH 7.5

Reconstitution: Please refer to the printed manual for detailed information.

Background: Protein S100-P; also known as Protein S100-E; S100 calcium-binding protein P; S100P and S100E; is a nucleus and cytoplasm protein which belongs to the S-100 family. S100P / S100E contains two EF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction; protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas; whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target; and could also serve as a biomarker for aggressive; hormone-refractory and metastatic prostate cancer.

Research Area: Signal Transduction, Cancer,